Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
372.4000 -1.15 (-0.31%)
NSE Jul 10, 2025 15:52 PM
Volume: 1.9M
 

logo
Biocon Ltd.
04 Dec 2017
372.40
-0.31%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research In a positive development for Biocon, the USFDA has approved Mylan's Ogivri, a biosimilar of Herceptin (Trastuzumab-dkst) co-developed with Biocon. The approval comes on the heels of a strong recommendation for approval of Biocon/Mylan's biosimilar Trastuzumab by the USFDA Oncologic Drugs Advisory Committee (ODAC) by a 16-0 vote in support of eligible indications of the reference product, on July 13, 2017. Herceptin, manufactured by Roche, is used to treat certain breast cancers...
Biocon Ltd. is trading above all available SMAs
More from Biocon Ltd.
Recommended